Canada's Research-Based Pharmaceutical Companies (Rx&D)

Canada's Research-Based Pharmaceutical Companies (Rx&D)

November 05, 2014 15:54 ET

Continued investment in targeted research provides hope for Prostate Cancer patient

OTTAWA, ONTARIO--(Marketwired - Nov. 5, 2014) -

Editors Note: There is a photo and a video associated with this press release.

Diagnosed with advanced prostate cancer at the age of 58, Stewart Campbell was left with some difficult choices. Since surgery or radiation would have only been qualified as palliative care, and because of the potential of unpleasant side effects, he chose medicine to control his prostate cancer. Stewart was offered the opportunity to participate in a phase 3 clinical trial for a new therapy, and he accepted.

His cancer has responded extremely well to the innovative medicine.

He has lived with cancer for 8 years and, thanks to continuing investment in targeted research, Stewart looks forward to the future new medicines that could become available.

"There's a good chance I'll still be living with this disease in 15 to 20 years. New drugs keep coming down the pipeline; innovative medicines are based on science and sound clinical trials," said Stewart.

Innovative medicines give people like Stewart a chance to continue to enjoy their families, work and live fully. Clinical trials help save Canadian lives by providing access to new, potentially life-saving medications and therapies, while allowing healthcare professionals and hospitals to introduce innovative therapies.

"These new medicines gave me the opportunity to continue to be productive in my work and spend quality time with my family," added Stewart.

Stewart now works with others living with prostate cancer to create awareness, educate and instill hope.

About Rx&D

Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents the men and women working for more than 50 member companies which invest more than $1 billion in research and development each year to fuel Canada's knowledge-based economy, contributing over $3 billion to the Canadian economy. Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, private payers, healthcare professionals and stakeholders in a highly ethical manner.

To view the photo associated with this press release, please visit the following link:

To view the video associated with this press release, please visit the following link:

Contact Information